Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4561 to 4575 of 8932 results

  1. What is the clinical and cost effectiveness, post treatment and at longer-term follow‑up, of behavioural activation compared with other psychological therapies in children aged 5 to 11 years and young people aged 12 to 18 years with mild or moderate to severe depression?

    Recommendation ID NG134/5 Question What is the clinical and cost effectiveness, post treatment and at longer-term follow‑up, of behavioural

  2. Behavioural interventions:- What is the effectiveness of behavioural interventions compared with usual care/advice for children with faltering growth?

    Recommendation ID NG75/3 Question Behavioural interventions:- What is the effectiveness of behavioural interventions compared with usual

  3. Behaviour change methods and resources:- What behaviour change methods and resources (such as phone apps, leaflets and messaging) help dental teams to provide people with support to improve their oral health?

    Recommendation ID NG30/3 Question Behaviour change methods and resources:- What behaviour change methods and resources (such as phone apps

  4. Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse

    Recommendation ID IPG669/1 Question Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse

  5. Bladder management strategies:- What are the long-term risks and effects on quality of life of different bladder management strategies for lower urinary tract dysfunction in people with neurological disease?

    Recommendation ID CG148/4 Question Bladder management strategies:- What are the long-term risks and effects on quality of life of different

  6. Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of fracture risk with FRAX?

    Recommendation ID CG146/4 Question Bone mineral density (BMD) with FRAX:- What is the added prognostic value of BMD in the assessment of

  7. What is the clinical utility of bone turnover markers in the diagnosis and management of primary hyperparathyroidism?

    Recommendation ID NG132/1 Question What is the clinical utility of bone turnover markers in the diagnosis and management of primary...

  8. Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when used routinely or according to clinical need in children and young people who are at Gross Motor Function Classification System (GMFCS) level I, II or III?

    Recommendation ID CG145/3 Question Botulinum toxin type A:- What is the clinical and cost effectiveness of botulinum toxin type A when

  9. Core outcome set for studies of management of Lyme disease:- Can a core outcome set be developed for clinical trials of management of Lyme disease?

    Recommendation ID NG95/1 Question Core outcome set for studies of management of Lyme disease:- Can a core outcome set be developed for

  10. Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment planning for people with melanoma?

    Recommendation ID NG14/02 Question Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment

  11. Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response to treatment?

    Recommendation ID NG14/01 Question Monitoring and response biomarkers: Can biomarkers accurately classify recurrence, progression and response

  12. Detection and management of respiratory disorders in primary and community care:- Can detection and management of respiratory disorders in adults with cerebral palsy be improved in primary and community care?

    Recommendation ID NG119/3 Question Detection and management of respiratory disorders in primary and community care:- Can detection and